Analysts have been eager to weigh in on the Healthcare sector with new ratings on AbSci (ABSI – Research Report), HilleVax, Inc (HLVX – Research Report) and Cabaletta Bio (CABA – Research Report).
AbSci (ABSI)
In a report released yesterday, Daniel Arias from Stifel Nicolaus maintained a Hold rating on AbSci, with a price target of $6.00. The company’s shares closed last Monday at $5.06.
According to TipRanks.com, Arias ‘ ranking currently consits of 0 on a 0-5 ranking scale, with an average return of
Currently, the analyst consensus on AbSci is a Strong Buy with an average price target of $8.00.
See Insiders’ Hot Stocks on TipRanks >>
HilleVax, Inc (HLVX)
Stifel Nicolaus analyst Stephen Willey maintained a Buy rating on HilleVax, Inc yesterday and set a price target of $34.00. The company’s shares closed last Monday at $16.42.
According to TipRanks.com, Willey is a 4-star analyst with an average return of
HilleVax, Inc has an analyst consensus of Strong Buy, with a price target consensus of $30.00, implying a 79.1% upside from current levels. In a report issued on March 21, H.C. Wainwright also reiterated a Buy rating on the stock with a $28.00 price target.
Cabaletta Bio (CABA)
In a report released yesterday, Benjamin Burnett from Stifel Nicolaus maintained a Buy rating on Cabaletta Bio, with a price target of $32.00. The company’s shares closed last Monday at $16.79.
According to TipRanks.com, Burnett is a 1-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Cabaletta Bio with a $33.20 average price target, which is an 87.5% upside from current levels. In a report issued on March 21, TD Cowen also maintained a Buy rating on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on ABSI:
